Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines

Our previous preclinical studies and a Phase I clinical trial DP6-001 have indicated that a polyvalent Env formulation was able to elicit broadly reactive antibody responses including low titer neutralizing antibody responses against viral isolates of subtypes A, B, C and AE. In the current report,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Hum Vaccin Immunother
Egile Nagusiak: Wang, Shixia, Chou, Te-hui, Hackett, Anthony, Efros, Veronica, Wang, Yan, Han, Dong, Wallace, Aaron, Chen, Yuxin, Hu, Guangnan, Liu, Shuying, Clapham, Paul, Arthos, James, Montefiori, David, Lu, Shan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2017
Gaiak:
Research Papers
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5718816/
https://ncbi.nlm.nih.gov/pubmed/28933684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2017.1380137
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak